advanced search

INJECTION

SUBCUJECT WBI: LOW-COST, LARGER VOLUME, HIGH-VISCOSITY WEARABLE BOLUS INJECTOR – USING STANDARD GLASS PRIMARY PACKAGING
WEARABLES
Claus Schmidt Moeller
SUBCUJECT WBI: LOW-COST, LARGER VOLUME, HIGH-VISCOSITY WEARABLE BOLUS INJECTOR – USING STANDARD GLASS PRIMARY PACKAGING
Claus Schmidt Moeller introduces the company’s wearable bolus injector for single use and discusses the advantages of the device.
OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES
OCULAR
Rainer Glockler
ten23 health
OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES
Rainer Glöckler, Carole Delauney, Dr Nicolas Eon and Katsuyuki Takeuchi discuss the myriad complexities of developing drug products for intravitreal injection, and how the partnership between swissfillon and Terumo can ease and accelerate these products to market. The first article, published in April, covered how swissfillon’s state-of-the-art filling line meets the complex requirements of ophthalmic drug products.
COMPARATIVE EXTRACTABLE STUDIES FOR INJECTABLES AND MEDICAL DEVICES ALIGNED WITH USP <1663> AND ISO 10993 GUIDELINES
INJECTION
Dr Matthias Bicker
SCHOTT Pharma
COMPARATIVE EXTRACTABLE STUDIES FOR INJECTABLES AND MEDICAL DEVICES ALIGNED WITH USP <1663> AND ISO 10993 GUIDELINES
Matthias Bicker, Michael Müller, Marc Mittermüller, Daniel Haines and Uwe Rothhaar discuss the regulatory requirements that need to be considered when designing an extractables and leachables study for a drug product or medical device. To illustrate the subject further, the authors provide two example studies, each following a different set of regulatory guidelines.
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
EXPERT VIEW
Dr Suresh Gupta
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
Suresh Gupta discusses the challenges of developing a PFS product for intravitreal injection, highlighting how designing for the intravitreal space, rather than the standard parenteral, imposes a number of additional requirements on the design.
HOSTAFORM<sup>®</sup> POM ECO-B – PROVEN, VERSATILE, EASY AND SUSTAINABLE
SUSTAINABILITY
Kevin Norfleet
Celanese
HOSTAFORM® POM ECO-B – PROVEN, VERSATILE, EASY AND SUSTAINABLE
Kevin Norfleet and Rob Haley discuss the need for environmentally sustainable materials in the medical device industry, and how Celanese’s Hostaform® MT® POM ECO-B meets that need, being an exact equivalent to the company’s existing material but produced using up to 97% bio-content using a potential greenhouse gas as feedstock, accounted for using the mass balance approach.
I-PLATFORM DEVICE: THE SMART DEVICE WITH APTITUDE
INJECTION
Jimmy Fan
CC Bio
I-PLATFORM DEVICE: THE SMART DEVICE WITH APTITUDE
Jimmy Fan outlines the capabilities and benefits of the I-Platform smart drug delivery device.
SURFACE-MEDIATED AGGREGATION – CONTROL OF THE LIQUID-SOLID INTERFACIAL STRESS
PREFILLED SYRINGES
Dr Shane Smith
Glycome BioPharma
SURFACE-MEDIATED AGGREGATION – CONTROL OF THE LIQUID-SOLID INTERFACIAL STRESS
Shane Smith, Eoin Scanlan and Paula Colavita discuss how the company’s technology has evolved to create a stable and biocompatible coating that maintains device performance and safety.
INTERVIEW WITH BENJAMIN DIETIKER, WEIDMANN MEDICAL TECHNOLOGY
INTERVIEW
Benjamin Dietiker
INTERVIEW WITH BENJAMIN DIETIKER, WEIDMANN MEDICAL TECHNOLOGY
Benjamin Dietiker, Weidmann Medical Technology, talks with ONdrugDelivery about how the company has successfully implemented a growth strategy by focusing on key areas, plans for expansion, the effect of covid-19 on the business, and how the company differentiates itself from larger competitors by focusing on quality and service.
ROOM FOR INNOVATION?
EXPERT VIEW
Darren Mansell
ROOM FOR INNOVATION?
Darren Mansell examines US FDA guidance on biosimilar interchangeability and asks whether there is room for innovation.
CONSIDERATIONS FOR DEVICE SELECTION IN PARENTERAL APPLICATIONS
INJECTION
Mark Tunkel
Nemera
CONSIDERATIONS FOR DEVICE SELECTION IN PARENTERAL APPLICATIONS
Mark Tunkel looks at the challenges involved in the selection of drug devices for combination products and the optimisation of the development process.
TOP FIVE DRUG DELIVERY TRENDS FOR 2021
EXPERT VIEW
Tom Oakley
TOP FIVE DRUG DELIVERY TRENDS FOR 2021
Tom Oakley provides an overview of the top five trends to expect in drug delivery in 2021.
PLATFORM TRAINING SOLUTIONS ADD VALUE FOR PHARMACEUTICAL COMPANIES
INJECTION
Alex Catino
Noble
PLATFORM TRAINING SOLUTIONS ADD VALUE FOR PHARMACEUTICAL COMPANIES
Alex Catino discusses the unmet need in healthcare for proper patient onboarding and training in the field of prefilled syringes and injection devices. Ms Catino uses Noble’s training device for Ypsomed’s YpsoMate® autoinjector as a case study for how bespoke training devices can be used to help improve the patient experience and adherence rates.
TACKLING PARENTERAL DRUG LABELLING’S SURGING COMPLEXITY
EXPERT VIEW
Lars Skole
TACKLING PARENTERAL DRUG LABELLING’S SURGING COMPLEXITY
Lars Skole discusses emerging trends and challenges associated with growing parenteral packaging and labelling complexity – and how pharmaceutical developers and manufacturers can meet the challenges ahead.
INJAY: SIMPLE BY CHOICE, ADAPTABLE BY DESIGN
CONNECTIVITY
Arnaud Guillet
Biocorp
INJAY: SIMPLE BY CHOICE, ADAPTABLE BY DESIGN
Arnaud Guillet discusses Biocorp’s Injay solution for adding connectivity to a wide variety of PFS devices, focusing on how Injay’s designed-in simplicity and flexibility makes it easily applicable across the spectrum of PFS platforms on the market today.
NEW ENGINE FOR PRIMARY CONTAINER INJECTORS: A POWERFUL MICRO LINEAR ACTUATOR
EARLY INSIGHT
Dr Brian Li
MicroMED Co Ltd
NEW ENGINE FOR PRIMARY CONTAINER INJECTORS: A POWERFUL MICRO LINEAR ACTUATOR
Brian Li, Jiunn-Ru Lai, Tsung-Chieh Cheng, Kuang-Hsiang Cheng, Min-Ru Wang, Chia-Chi Tina Feng, and Wen-Chi Huang introduce the company’s new engine for primary container injectors, the Primary Actuator, which targets the unmet needs in the autoinjector and wearable injector market as the market shifts towards large injection volumes.
BUILDING A BETTER PREFILLED SYRINGE FOR COVID-19 VACCINE PACKAGING
PREFILLED SYRINGES
Carina Van Eester
Datwlyer
BUILDING A BETTER PREFILLED SYRINGE FOR COVID-19 VACCINE PACKAGING
Carina Van Eester shares key learnings since the launch of the company’s NeoFlex plungers at the start of the covid-19 pandemic.
STEVANATO & EITAN BRING NEXT-GENERATION WEARABLE DRUG DELIVERY SOLUTIONS TO MARKET
WEARABLES
Chiara Mussoi
Stevanato Group
STEVANATO & EITAN BRING NEXT-GENERATION WEARABLE DRUG DELIVERY SOLUTIONS TO MARKET
Chiara Mussoi, Riccardo Prete and Mindy Katz outline the benefits of collaboration when it comes to bringing wearable drug delivery solutions to market.
AN INCLUSIVE APPROACH TO THE DEVELOPMENT OF PLATFORM MEDICAL DEVICES
PREFILLED SYRINGES
Finola Austin
Owen Mumford
AN INCLUSIVE APPROACH TO THE DEVELOPMENT OF PLATFORM MEDICAL DEVICES
Finola Austin discusses the difficulties presented by designing a user testing programme for platform devices when the target patient population is as yet unknown, and presents the testing framework based on seven user groups that Owen Mumford uses to meet this challenge.
BD HYLOK™ – GLASS PREFILLABLE SYRINGE FOR IV APPLICATIONS
PREFILLED SYRINGES
Sophie Trémeau
BD (Becton Dickinson & Company)
BD HYLOK™ – GLASS PREFILLABLE SYRINGE FOR IV APPLICATIONS
Sophie Trémeau, Maxime Nicolas and Myriam Leszczynski discuss BD Hylok™, a prefillable glass syringe for intravenous applications, including the rigorous testing BD Hylok™ has undergone and the regulatory support BD is able to provide to its pharmaceutical partners.
INNOVATING IN THE VISCOSITY DESIGN SPACE: A NEW 2.25 ML AUTOINJECTOR PLATFORM
INJECTION
Karima Yadi
BD (Becton Dickinson & Company)
INNOVATING IN THE VISCOSITY DESIGN SPACE: A NEW 2.25 ML AUTOINJECTOR PLATFORM
Karima Yadi and Lionel Maritan discuss BD’s response to the need for an autoinjector platform that reconciles the demands of biologics with safety, reliability and ease of use during self-injection: the Intevia™ 2.25 mL disposable autoinjector.
HOW TO KEEP THE GRANDFATHER DILEMMA FROM INTERRUPTING DRUG REDEVELOPMENT
INJECTION
Chris Rojewski
Pfizer CentreOne
HOW TO KEEP THE GRANDFATHER DILEMMA FROM INTERRUPTING DRUG REDEVELOPMENT
Chris Rojewski provides programme insights into approval pathways for the redevelopment of pharmaceutical compounds.
INTRODUCING ISOSORBIDE: A SUSTAINABLE, SAFE, HIGH-PERFORMANCE, PLANT-BASED FEEDSTOCK FOR PACKAGING
SUSTAINABILITY
Jiae Kim
Roquette
INTRODUCING ISOSORBIDE: A SUSTAINABLE, SAFE, HIGH-PERFORMANCE, PLANT-BASED FEEDSTOCK FOR PACKAGING
Jiae Kim introduces isosorbide, a plant starch-derived diol made from renewable feedstock that has wide ranging applications across polymer materials for a variety of industries.
CONNECTED DRUG DELIVERY: ACHIEVING OPTIMAL BENEFITS THROUGH SMART COLLABORATION
EXPERT VIEW
George I’ons
CONNECTED DRUG DELIVERY: ACHIEVING OPTIMAL BENEFITS THROUGH SMART COLLABORATION
George I’ons discusses the challenges developing connected devices presents to key market stakeholders when it comes to successful rollout and implementation. Additionally, he considers the perspectives of these market players, as well as the patients themselves, with respect to how connected drug delivery devices can help them to better achieve their desired outcomes.
MEDICAL DEVICE DESIGN STRATEGY FOR A CONNECTED FUTURE
CONNECTIVITY
Mr Michael Kiely
Jabil Healthcare
MEDICAL DEVICE DESIGN STRATEGY FOR A CONNECTED FUTURE
Michael Kiely, Laura Marsden, Peter Stringer, and David Boyle discuss the design challenges at the electromechanical interface and encourage manufacturers to adopt a standardised approach for connecting medical devices to the cloud.
Top